Arun Wiita, MD, PhD, University of California, San Francisco, CA, talks on the use of proteomic technologies to identify novel immunotherapeutic targets to treat multiple myeloma and to find biomarkers of resistance to immunotherapy. Dr Wiita notably mentions CCR10, a chemokine receptor that was found to be uniformly highly expressed on myeloma plasma cells. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.